GlassScriptPhysician profile
Indrani Gill
NPI 1174654818
$1,797.39
in general payments reported to CMS, 2019-2025
23 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $433 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.96 |
| Education | $236.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $158.46 | 2025 | Vyloy, Xtandi |
| Novartis Pharmaceuticals Corporation | $153.94 | 2024-2025 | |
| Janssen Biotech, INC. | $148.87 | 2024-2025 | Erleada, Rybrevant |
| Array Biopharma INC | $135.68 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Celgene Corporation | $117.77 | 2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $113.41 | 2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $109.85 | 2025 | |
| Eisai INC. | $104.24 | 2025 | |
| Sobi, INC | $100.62 | 2024-2025 | |
| Glaxosmithkline, LLC. | $79.20 | 2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $70.65 | 2024-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $68.67 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $56.44 | 2024-2025 | Xpovio |
| Puma Biotechnology, INC. | $53.65 | 2025 | |
| Aveo Pharmaceuticals, INC. | $49.64 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.90 | 2025 | |
| Incyte Corporation | $47.32 | 2024-2025 | Monjuvi, Jakafi |
| Genentech USA, INC. | $46.37 | 2024-2025 | Itovebi, Tecentriq |
| Rigel Pharmaceuticals, INC. | $36.66 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Agios Pharmaceuticals, INC. | $33.89 | 2024 | Pyrukynd |
| Abbvie INC. | $23.71 | 2025 | |
| Coherus Oncology, INC. | $20.83 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.62 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indrani Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.